These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 35023177)

  • 21. Letermovir for Cytomegalovirus Prevention in Adolescent Patients Following Hematopoietic Cell Transplantation.
    P Daukshus N; Cirincione A; Siver M; Mathew S; Kunvarjee B; Chan A; Boelens JJ; Seo SK; Papanicolaou GA; Kernan NA
    J Pediatric Infect Dis Soc; 2022 Jul; 11(7):337-340. PubMed ID: 35472147
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Delayed-onset cytomegalovirus infection is frequent after discontinuing letermovir in cord blood transplant recipients.
    Hill JA; Zamora D; Xie H; Thur LA; Delaney C; Dahlberg A; Pergam SA; Leisenring WM; Boeckh M; Milano F
    Blood Adv; 2021 Aug; 5(16):3113-3119. PubMed ID: 34402885
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Letermovir for Secondary Prophylaxis of Cytomegalovirus Infection and Disease after Allogeneic Hematopoietic Cell Transplantation: Results from the French Compassionate Program.
    Robin C; Thiebaut A; Alain S; Sicre de Fontbrune F; Berceanu A; D'Aveni M; Ceballos P; Redjoul R; Nguyen-Quoc S; Bénard N; Pahlavan-Grumel G; Cordonnier C
    Biol Blood Marrow Transplant; 2020 May; 26(5):978-984. PubMed ID: 32035273
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Extended letermovir administration, beyond day 100, is effective for CMV prophylaxis in patients with graft versus host disease.
    Bansal R; Gordillo CA; Abramova R; Assal A; Mapara MY; Pereira MR; Reshef R
    Transpl Infect Dis; 2021 Apr; 23(2):e13487. PubMed ID: 33034124
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of letermovir for prevention of cytomegalovirus infection after allogeneic haematopoietic stem cell transplantation.
    Razonable RR
    Curr Opin Infect Dis; 2018 Aug; 31(4):286-291. PubMed ID: 29746444
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Maribavir for Preemptive Treatment of Cytomegalovirus Reactivation.
    Maertens J; Cordonnier C; Jaksch P; Poiré X; Uknis M; Wu J; Wijatyk A; Saliba F; Witzke O; Villano S
    N Engl J Med; 2019 Sep; 381(12):1136-1147. PubMed ID: 31532960
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Emergence of letermovir resistance in solid organ transplant recipients with ganciclovir resistant cytomegalovirus infection: A case series and review of the literature.
    Hofmann E; Sidler D; Dahdal S; Bittel P; Suter-Riniker F; Manuel O; Walti LN; Hirzel C
    Transpl Infect Dis; 2021 Jun; 23(3):e13515. PubMed ID: 33210830
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of UL56 Mutations before Letermovir Therapy in Refractory Cytomegalovirus Transplant Recipients.
    Santos Bravo M; Tilloy V; Plault N; Palomino SS; Mosquera MM; Navarro Gabriel M; Fernández Avilés F; Suárez Lledó M; Rovira M; Moreno A; Linares L; Bodro M; Hantz S; Alain S; Marcos MÁ
    Microbiol Spectr; 2022 Apr; 10(2):e0019122. PubMed ID: 35343771
    [No Abstract]   [Full Text] [Related]  

  • 29. CMV prophylaxis with letermovir significantly improves graft and relapse free survival following allogeneic stem cell transplantation.
    Malagola M; Radici V; Farina M; Pellizzeri S; Spoldi F; Morello E; Polverelli N; Buttini EA; Bernardi S; Re F; Leoni A; Signorini L; Caruso A; Russo D
    Bone Marrow Transplant; 2024 Jan; 59(1):138-140. PubMed ID: 37857841
    [No Abstract]   [Full Text] [Related]  

  • 30. Letermovir Prophylaxis Decreases Burden of Cytomegalovirus (CMV) in Patients at High Risk for CMV Disease Following Hematopoietic Cell Transplant.
    Johnsrud JJ; Nguyen IT; Domingo W; Narasimhan B; Efron B; Brown JW
    Biol Blood Marrow Transplant; 2020 Oct; 26(10):1963-1970. PubMed ID: 32653623
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Maribavir: 1263W94, Benzimidavir, GW 1263, GW 1263W94, VP41263.
    Drugs R D; 2007; 8(3):188-92. PubMed ID: 17472414
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Letermovir for prophylaxis of cytomegalovirus in allogeneic hematopoietic stem cell recipients.
    Cho JC; Le AD; Locke SC
    Drugs Today (Barc); 2018 Jun; 54(6):361-368. PubMed ID: 29998227
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation.
    Marty FM; Ljungman P; Chemaly RF; Maertens J; Dadwal SS; Duarte RF; Haider S; Ullmann AJ; Katayama Y; Brown J; Mullane KM; Boeckh M; Blumberg EA; Einsele H; Snydman DR; Kanda Y; DiNubile MJ; Teal VL; Wan H; Murata Y; Kartsonis NA; Leavitt RY; Badshah C
    N Engl J Med; 2017 Dec; 377(25):2433-2444. PubMed ID: 29211658
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Successful Treatment of UL97 Mutation Ganciclovir-Resistant Cytomegalovirus Viremia in a Renal Transplant Recipient With Letermovir and Adjunct Hyperimmune Cytomegalovirus Immunoglobulin: A Case Report.
    Pearston AP; Ingemi AI; Ripley K; Wilson TJ; Gruber J; McMahon M; Sutton S; Khardori N
    Transplant Proc; 2021 May; 53(4):1284-1287. PubMed ID: 33715819
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Letermovir: First Global Approval.
    Kim ES
    Drugs; 2018 Jan; 78(1):147-152. PubMed ID: 29288370
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Single-center experience with use of letermovir for CMV prophylaxis or treatment in thoracic organ transplant recipients.
    Aryal S; Katugaha SB; Cochrane A; Brown AW; Nathan SD; Shlobin OA; Ahmad K; Marinak L; Chun J; Fregoso M; Desai S; King C
    Transpl Infect Dis; 2019 Dec; 21(6):e13166. PubMed ID: 31487755
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Letermovir successfully used for secondary prophylaxis in a heart transplant recipient with ganciclovir-resistant cytomegalovirus syndrome (UL97 mutation).
    Chong PP; Teiber D; Prokesch BC; Arasaratnam RJ; Peltz M; Drazner MH; Garg S
    Transpl Infect Dis; 2018 Oct; 20(5):e12965. PubMed ID: 29989279
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation.
    Chemaly RF; Ullmann AJ; Stoelben S; Richard MP; Bornhäuser M; Groth C; Einsele H; Silverman M; Mullane KM; Brown J; Nowak H; Kölling K; Stobernack HP; Lischka P; Zimmermann H; Rübsamen-Schaeff H; Champlin RE; Ehninger G;
    N Engl J Med; 2014 May; 370(19):1781-9. PubMed ID: 24806159
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Letermovir prophylaxis lowers the incidence of Non-CMV infections after allogeneic hematopoietic cell transplantation.
    Bashey SZ; Solomon SR; Zhang X; Morris LE; Kent Holland H; Bachier L; Solh MM
    Bone Marrow Transplant; 2024 Apr; 59(4):564-565. PubMed ID: 38263393
    [No Abstract]   [Full Text] [Related]  

  • 40. [Cytomegalovirus infections following allogeneic hematopoietic stem cell transplantation: prophylaxis and treatment].
    Katayama Y; Iwato K
    Rinsho Ketsueki; 2019; 60(6):635-645. PubMed ID: 31281156
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.